
Sun Pharmaceutical (SUNPHARMA) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
137.9B
Gross Profit
109.7B
79.58%
Operating Income
33.7B
24.46%
Net Income
22.9B
16.63%
EPS (Diluted)
₹9.50
Balance Sheet Metrics
Total Assets
921.0B
Total Liabilities
196.1B
Shareholders Equity
724.9B
Debt to Equity
0.27
Cash Flow Metrics
Revenue & Profitability Trend
Sun Pharmaceutical Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 520.4B | 477.6B | 432.8B | 384.3B | 332.3B |
Cost of Goods Sold | 122.0B | 120.7B | 119.4B | 103.5B | 98.9B |
Gross Profit | 398.4B | 356.9B | 313.4B | 280.7B | 233.5B |
Gross Margin % | 76.6% | 74.7% | 72.4% | 73.1% | 70.3% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | 103.0B | 92.2B | 80.4B | 54.7B | 48.7B |
Other Operating Expenses | 48.7B | 46.8B | 37.4B | 107.6B | 33.6B |
Total Operating Expenses | 151.7B | 139.0B | 117.8B | 162.3B | 82.2B |
Operating Income | 125.8B | 104.7B | 92.8B | 81.0B | 64.1B |
Operating Margin % | 24.2% | 21.9% | 21.4% | 21.1% | 19.3% |
Non-Operating Items | |||||
Interest Income | 12.3B | 10.2B | 3.8B | 5.5B | 2.1B |
Interest Expense | 2.3B | 2.4B | 1.7B | 1.3B | 1.4B |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 137.5B | 110.9B | 94.1B | 44.8B | 28.0B |
Income Tax | 27.7B | 14.4B | 8.5B | 10.8B | 5.1B |
Effective Tax Rate % | 20.2% | 13.0% | 9.0% | 24.0% | 18.4% |
Net Income | 109.6B | 96.1B | 85.1B | 33.9B | 22.7B |
Net Margin % | 21.1% | 20.1% | 19.7% | 8.8% | 6.8% |
Key Metrics | |||||
EBITDA | 167.3B | 142.9B | 122.9B | 113.2B | 90.5B |
EPS (Basic) | ₹45.60 | ₹39.90 | ₹35.30 | ₹13.60 | ₹12.10 |
EPS (Diluted) | ₹45.60 | ₹39.90 | ₹35.30 | ₹13.60 | ₹12.10 |
Basic Shares Outstanding | 2399334970 | 2399334970 | 2399334970 | 2406419118 | 2399334970 |
Diluted Shares Outstanding | 2399334970 | 2399334970 | 2399334970 | 2406419118 | 2399334970 |
Income Statement Trend
Sun Pharmaceutical Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 102.7B | 92.9B | 46.2B | 45.1B | 62.7B |
Short-term Investments | 160.5B | 100.4B | 107.9B | 81.5B | 32.9B |
Accounts Receivable | 130.5B | 112.5B | 114.4B | 105.9B | 90.6B |
Inventory | 102.4B | 98.7B | 105.1B | 90.0B | 90.0B |
Other Current Assets | 733.5M | 646.7M | 862.5M | 540.9M | 508.2M |
Total Current Assets | 526.2B | 434.7B | 398.8B | 350.1B | 304.4B |
Non-Current Assets | |||||
Property, Plant & Equipment | 100.4B | 101.9B | 103.9B | 103.7B | 102.3B |
Goodwill | 269.0B | 258.6B | 260.4B | 191.3B | 182.4B |
Intangible Assets | 90.2B | 86.7B | 93.3B | 60.3B | 56.6B |
Long-term Investments | - | 0 | 100.0K | 5.5M | 2.0M |
Other Non-Current Assets | 5.4B | 4.7B | 51.6B | -1.0M | 5.4B |
Total Non-Current Assets | 394.8B | 419.9B | 408.6B | 347.8B | 372.2B |
Total Assets | 921.0B | 854.6B | 807.4B | 698.0B | 676.7B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 61.8B | 56.5B | 56.8B | 44.8B | 39.7B |
Short-term Debt | 20.0B | 29.7B | 63.3B | 8.1B | 29.7B |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 10.4B | 9.6B | 4.9B | 5.1B | 5.1B |
Total Current Liabilities | 181.9B | 169.8B | 199.1B | 172.0B | 161.5B |
Non-Current Liabilities | |||||
Long-term Debt | 3.6B | 3.0B | 5.6B | 4.8B | 9.0B |
Deferred Tax Liabilities | 1.9B | 1.6B | 316.9M | 318.6M | 445.1M |
Other Non-Current Liabilities | 191.8M | 112.0M | 129.5M | 157.0M | 333.8M |
Total Non-Current Liabilities | 14.2B | 13.7B | 15.2B | 15.3B | 20.4B |
Total Liabilities | 196.1B | 183.6B | 214.3B | 187.3B | 181.9B |
Equity | |||||
Common Stock | 2.4B | 2.4B | 2.4B | 2.4B | 2.4B |
Retained Earnings | 578.6B | 501.5B | 436.1B | 376.5B | 366.0B |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 724.9B | 671.1B | 593.2B | 510.7B | 494.8B |
Key Metrics | |||||
Total Debt | 23.6B | 32.7B | 68.9B | 12.9B | 38.7B |
Working Capital | 344.3B | 264.9B | 199.8B | 178.1B | 143.0B |
Balance Sheet Composition
Sun Pharmaceutical Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 137.5B | 110.9B | 94.1B | 44.8B | 28.0B |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | -16.6B | 8.1B | -30.4B | -33.5B | 16.3B |
Operating Cash Flow | 110.8B | 110.8B | 61.4B | 6.9B | 43.5B |
Investing Activities | |||||
Capital Expenditures | -20.7B | -21.7B | -20.6B | -14.3B | -10.7B |
Acquisitions | -3.2B | -2.3B | -48.4B | -7.2B | -616.0M |
Investment Purchases | -344.7B | -305.7B | -225.3B | -246.6B | -188.2B |
Investment Sales | 306.5B | 315.9B | 210.5B | 208.7B | 202.0B |
Investing Cash Flow | -62.0B | -13.8B | -83.9B | -59.4B | 2.4B |
Financing Activities | |||||
Share Repurchases | -29.0B | -773.9M | 0 | -1.9B | -1.9B |
Dividends Paid | -36.1B | -29.0B | -25.2B | -21.6B | -15.6B |
Debt Issuance | 33.6B | 45.7B | 81.6B | 16.6B | 66.0B |
Debt Repayment | -43.4B | -81.1B | -29.0B | -44.0B | -108.0B |
Financing Cash Flow | -75.4B | -63.7B | 26.1B | -49.8B | -56.9B |
Free Cash Flow | 119.4B | 99.3B | 28.7B | 74.9B | 50.0B |
Net Change in Cash | -26.6B | 33.4B | 3.6B | -102.3B | -11.1B |
Cash Flow Trend
Sun Pharmaceutical Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
36.63
Forward P/E
48.56
Price to Book
5.27
Price to Sales
7.13
PEG Ratio
48.56
Profitability Ratios
Profit Margin
19.29%
Operating Margin
24.34%
Return on Equity
15.08%
Return on Assets
11.87%
Financial Health
Current Ratio
2.89
Debt to Equity
3.26
Beta
0.31
Per Share Data
EPS (TTM)
₹43.32
Book Value per Share
₹300.99
Revenue per Share
₹224.24
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
sunpharma | 3.8T | 36.63 | 5.27 | 15.08% | 19.29% | 3.26 |
Divi's Laboratories | 1.6T | 68.03 | 10.49 | 14.64% | 23.89% | 0.03 |
Torrent | 1.2T | 60.57 | 15.93 | 25.18% | 16.92% | 42.81 |
Cipla | 1.2T | 22.27 | 3.85 | 16.85% | 19.62% | 1.40 |
Mankind Pharma | 1.0T | 53.19 | 7.10 | 13.67% | 14.66% | 58.43 |
Dr. Reddy's | 1.0T | 17.79 | 2.88 | 17.71% | 16.99% | 13.75 |
Financial data is updated regularly. All figures are in the company's reporting currency.